Amneal Pharmaceuticals, Inc.
AMRX
$11.82
-$0.37-3.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.50% | 9.81% | 13.42% | 16.73% | 12.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.50% | 9.81% | 13.42% | 16.73% | 12.32% |
| Cost of Revenue | 8.17% | 7.86% | 13.64% | 16.26% | 11.30% |
| Gross Profit | 11.80% | 13.23% | 13.05% | 17.55% | 14.14% |
| SG&A Expenses | 11.45% | 8.62% | 9.53% | 10.88% | 8.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -463.33% | -3,656.07% | -3,407.53% | 18.28% | 64.27% |
| Total Operating Expenses | 8.98% | 8.96% | 12.73% | 15.19% | 10.96% |
| Operating Income | 13.06% | 15.71% | 18.36% | 28.71% | 22.67% |
| Income Before Tax | 155.75% | 177.24% | 154.52% | -36.61% | -446.56% |
| Income Tax Expenses | -52.68% | 116.47% | 83.46% | 123.18% | 822.52% |
| Earnings from Continuing Operations | 139.34% | 138.47% | 126.95% | -51.63% | -477.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -36.19% | -15.58% | 6.03% | -21.94% | -33.53% |
| Net Income | 103.20% | 101.93% | 92.27% | -39.16% | -1,886.83% |
| EBIT | 13.06% | 15.71% | 18.36% | 28.71% | 22.67% |
| EBITDA | 10.21% | 12.96% | 13.21% | 16.91% | 11.04% |
| EPS Basic | 102.62% | 101.59% | 92.50% | -22.41% | -1,134.95% |
| Normalized Basic EPS | 380.92% | -17.49% | -559.57% | -285.83% | -91.14% |
| EPS Diluted | 102.39% | 101.34% | 92.56% | -20.20% | -1,311.84% |
| Normalized Diluted EPS | 351.32% | -30.94% | -569.47% | -285.34% | -91.15% |
| Average Basic Shares Outstanding | 6.76% | 22.67% | 44.32% | 75.61% | 91.28% |
| Average Diluted Shares Outstanding | 8.59% | 22.94% | 45.85% | 75.36% | 90.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |